CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative... read more →
Tune in to hear John Flavin and the Chicago Biomedical Consortium Entrepreneurial Fellows engage with Jim, aiming to learn more about the life sciences industry and the different means of... read more →
Biotech 2050 Podcast: Ep. 102 – Vanquishing Parkinson’s Disease, Jim Sullivan, PhD, Co-founder & CEO, Vanqua Bio
Dr. Sullivan and Biotech 2050 Podcast host Alok Tayi discuss Vanqua Bio’s platform, lead programs, and our focus on Parkinson's disease. Tune in...
Vanqua Bio today announced that the company will participate in the Stifel 2022 CNS Day Conference, which is being held virtually March 28-29. “Vanqua Bio was founded to transform a cutting-edge... read more →
Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases
– Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies – – Lead program targets Parkinson's disease and all forms of... read more →